



Application No. 10/782,337  
Amendment Dated June 1, 2006  
Reply to Office Action of March 1, 2006

22. (Original) The method of claim 15 wherein said osteoporosis is postmenopausal osteoporosis.

23. (Original) The method of claim 15 wherein 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> is administered to a human in a dosage of from about 0.01  $\mu$ g to about 100  $\mu$ g per day.

24. (Original) The method of claim 15 wherein 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> is administered to a human in a dosage of from about 0.1  $\mu$ g to about 10  $\mu$ g per day.

25. (Original) The method of claim 15 wherein 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> is administered to an animal in a dosage of from about 0.0001  $\mu$ g to about 700  $\mu$ g per day.

26.-67. (Cancelled)